The Natural Path
- PRP Therapy
- Shockwave Therapy
- Ozone Therapy
- Arthritis Treatment
- Peptide Therapy
Portland, OR
Portland supports a regenerative medicine market shaped by both private clinics and regional academic medicine. Local referral networks run through Oregon Health & Science University (OHSU) and Legacy Health, and stem cell practice in the area spans the Pearl District, Northwest, and Lake Oswego. Patient demand splits across three buckets: orthopedic injections for active adults and aging athletes, neurological and autoimmune protocols marketed to longevity-focused patients, and IV-based allogeneic products offered by private wellness clinics. The FDA classifies most stem cell injections for orthopedic, neurological, or longevity use as investigational biologics under 21 CFR Part 1271, meaning they require either a Biologics License or an active Investigational New Drug authorization. Autologous bone marrow and adipose products may qualify as Section 361 when minimally manipulated and used for homologous function. Oregon regulates physician practice through the Oregon Medical Board. There is no Oregon-specific stem cell statute, so federal 21 CFR Part 1271 rules apply. The state's bioethics climate has drawn academic trial activity at OHSU. The 10 Portland clinics listed below have been reviewed against our vetting criteria, including federal NPI lookup, OIG exclusion screening, and Oregon Medical Board licensure checks.
Regulatory context
Oregon cellular therapy is governed by 21 CFR Part 1271. Section 361 covers minimally manipulated HCT/Ps used for homologous use without premarket approval. Section 351 covers products that are more than minimally manipulated, used non-homologously, or combined with another article, and these require an IND for clinical use or a BLA for marketing. Most stem cell, stromal vascular fraction, and exosome therapies marketed in Oregon for orthopedic, neurologic, and longevity indications are Section 351 biologics that lack FDA approval. Oregon licenses naturopathic doctors with one of the broadest scopes in the country, which can affect who legally administers some therapies.
The FDA has corresponded with Oregon providers offering cellular therapies. The Oregon Medical Board has disciplined physicians for unprofessional conduct including misleading regenerative medicine advertising. The Oregon Board of Naturopathic Medicine has disciplinary authority over NDs operating outside scope. The Oregon Attorney General has used the Oregon Unlawful Trade Practices Act to pursue providers making unsupported clinical claims. Federal warning letters apply nationally.